Cees G. M. Kallenberg
#135,920
Most Influential Person Now
Cees G. M. Kallenberg's AcademicInfluence.com Rankings
Cees G. M. Kallenbergphilosophy Degrees
Philosophy
#6862
World Rank
#9972
Historical Rank
Logic
#3956
World Rank
#5191
Historical Rank

Download Badge
Philosophy
Cees G. M. Kallenberg's Degrees
- Doctorate Medicine University of Amsterdam
- PhD Medicine University of Amsterdam
Why Is Cees G. M. Kallenberg Influential?
(Suggest an Edit or Addition)Cees G. M. Kallenberg's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis. (2010) (1810)
- Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis (2012) (885)
- Association of Chronic Nasal Carriage of Staphylococcus aureus and Higher Relapse Rates in Wegener Granulomatosis (1994) (729)
- Efficacy of remission-induction regimens for ANCA-associated vasculitis. (2013) (581)
- International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies (2013) (471)
- Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. (2010) (444)
- Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. (2007) (356)
- Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. (2014) (339)
- Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. (2002) (333)
- Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. (2010) (319)
- The complement system in systemic autoimmune disease. (2010) (314)
- Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis (2017) (270)
- Transancestral mapping and genetic load in systemic lupus erythematosus (2017) (253)
- Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. (2000) (222)
- Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. (2011) (222)
- Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides (2006) (211)
- Leukocyte activation in sepsis; correlations with disease state and mortality (2000) (207)
- Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study (2011) (204)
- Health-related quality of life, employment and disability in patients with Sjogren's syndrome. (2009) (200)
- Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases (1993) (195)
- Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. (2002) (191)
- Complement Activation Is Involved in Renal Damage in Human Antineutrophil Cytoplasmic Autoantibody Associated Pauci-Immune Vasculitis (2009) (189)
- Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. (2008) (187)
- Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. (2007) (184)
- CYCLOPHOSPHAMIDE AND SUPPRESSOR CELL FUNCTION (1981) (180)
- The Effect of Two Different Dosages of Intravenous Immunoglobulin on the Incidence of Recurrent Infections in Patients with Primary Hypogammaglobulinemia (2001) (178)
- Accelerated atherosclerosis in patients with Wegener’s granulomatosis (2004) (165)
- Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. (2011) (163)
- EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis (2010) (159)
- T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG) (1994) (152)
- Progression of salivary gland dysfunction in patients with Sjögren’s syndrome (2006) (147)
- High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus (2011) (145)
- ANCA-associated vasculitides—advances in pathogenesis and treatment (2010) (143)
- Pathogenesis of ANCA-associated vasculitides (2011) (141)
- Staphylococcus aureus and Wegener's granulomatosis (2001) (136)
- Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus (2006) (134)
- The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. (2001) (130)
- Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. (2011) (128)
- Pathogenesis of PR3-ANCA associated vasculitis. (2008) (127)
- Key advances in the clinical approach to ANCA-associated vasculitis (2014) (126)
- Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. (2003) (125)
- European therapeutic trials in ANCA‐associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials EUROPEAN COMMUNITY STUDY GROUP ON CLINICAL TRIALS IN SYSTEMIC VASCULITIS ECSYSVASTRIAL (BMHl‐Cr93‐1078) (1995) (125)
- Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 (2016) (122)
- High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. (2012) (119)
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. (2015) (119)
- Neutrophil‐activating potential of antineutrophil cytoplasm autoantibodies (2003) (116)
- Preclinical validation of salivary biomarkers for primary Sjögren's syndrome (2010) (115)
- Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus (2011) (112)
- Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. (1996) (111)
- Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis (2011) (109)
- The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long term observation (1997) (108)
- The Fc gamma RIIIA-158F allele is a risk factor for systemic lupus erythematosus (1998) (107)
- The environment, geoepidemiology and ANCA-associated vasculitides. (2010) (107)
- Neutrophil‐Related Gene Expression and Low‐Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2015) (106)
- Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. (2012) (103)
- Churg-Strauss syndrome: just one disease entity? (2005) (103)
- Identification of autoantibody biomarkers for primary Sjögren's syndrome using protein microarrays (2011) (98)
- Epstein-Barr Virus–DNA Load Monitoring Late After Lung Transplantation: A Surrogate Marker of the Degree of Immunosuppression and a Safe Guide to Reduce Immunosuppression (2007) (98)
- Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. (2004) (98)
- Monocyte activation in patients with Wegener’s granulomatosis (1999) (97)
- Regulation of Cytokine‐Induced HIF‐1α Expression in Rheumatoid Synovial Fibroblasts (2007) (96)
- The prototypic tissue pentraxin PTX3, in contrast to the short pentraxin serum amyloid P, inhibits phagocytosis of late apoptotic neutrophils by macrophages. (2004) (96)
- The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis (2010) (96)
- Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. (1998) (96)
- Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages. (2003) (93)
- Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. (2008) (90)
- ANCA-negative pauci-immune crescentic glomerulonephritis (2009) (86)
- Pathophysiology of ANCA-Associated Small Vessel Vasculitis (2010) (86)
- Patients' perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: a comparison with Wegener's granulomatosis. (2002) (84)
- Anti-C1q autoantibodies. (2008) (82)
- Autoantibodies against Protective Molecules—C1q, C‐Reactive Protein, Serum Amyloid P, Mannose‐Binding Lectin, and Apolipoprotein A1 (2007) (82)
- Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus (2007) (82)
- Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention. (2013) (80)
- Vasculitis and infections: Contribution to the issue of autoimmunity reviews devoted to “autoimmunity and infection” (2008) (79)
- Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. (2009) (79)
- Coexpression of CD177 and membrane proteinase 3 on neutrophils in antineutrophil cytoplasmic autoantibody-associated systemic vasculitis: anti-proteinase 3-mediated neutrophil activation is independent of the role of CD177-expressing neutrophils. (2009) (79)
- Site-Specific Inhibition of Glomerulonephritis Progression by Targeted Delivery of Dexamethasone to Glomerular Endothelium (2007) (78)
- Treatment of Mucosa-associated Lymphoid Tissue Lymphoma in Sjögren’s Syndrome: A Retrospective Clinical Study (2011) (78)
- Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial (2012) (78)
- Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission. (2011) (78)
- Systems biology analysis of Sjögren's syndrome and mucosa-associated lymphoid tissue lymphoma in parotid glands. (2009) (76)
- Molecular genetic analyses of human NKG2C (KLRC2) gene deletion. (2004) (76)
- Rats and mice immunised with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes (2007) (76)
- Myeloperoxidase–Antineutrophil Cytoplasmic Antibody (ANCA)–Positive and ANCA‐Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets (2016) (74)
- Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors (2008) (74)
- Hypoxia inducible factor-1-alpha (HIF-1alpha) is related to both angiogenesis and inflammation in rheumatoid arthritis. (2009) (71)
- Infectious triggers for vasculitis (2014) (70)
- Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. (1990) (69)
- Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis (2007) (69)
- Ultraviolet light and cutaneous lupus (2006) (68)
- Association of small life events with self reports of tic severity in pediatric and adult tic disorder patients: a prospective longitudinal study. (2004) (67)
- Relative Contribution of Attention-Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, and Tic Severity to Social and Behavioral Problems in Tic Disorders (2004) (66)
- Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease (2011) (66)
- Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. (2007) (65)
- Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus (2010) (65)
- T-helper cells as new players in ANCA-associated vasculitides (2011) (65)
- Increased Expression of Toll-Like Receptors by Monocytes and Natural Killer Cells in ANCA-Associated Vasculitis (2011) (64)
- Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. (2009) (63)
- New advances in the pathogenesis of ANCA-associated vasculitides. (2009) (62)
- Cellular immunity in Wegener's granulomatosis: characterizing T lymphocytes. (2009) (62)
- Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. (2011) (61)
- Parotid sialography for diagnosing Sjögren syndrome. (2002) (61)
- Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis. (2006) (61)
- B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a double-blind, placebo-controlled study. (2011) (61)
- Influenza vaccination in systemic lupus erythematosus: safe and protective? (2007) (60)
- Longitudinal study on premature atherosclerosis in patients with systemic lupus erythematosus. (2009) (60)
- Bacterial infections in Wegener's granulomatosis: mechanisms potentially involved in autoimmune pathogenesis (2011) (60)
- Urinary T cells in active lupus nephritis show an effector memory phenotype (2010) (59)
- Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations (2012) (57)
- Pulmonary function in systemic lupus erythematosus is related to distinct clinical, serologic, and nailfold capillary patterns. (1992) (57)
- Pathogenesis of ANCA-Associated Vasculitis, an Update (2011) (57)
- Is disturbed clearance of apoptotic keratinocytes responsible for UVB-induced inflammatory skin lesions in systemic lupus erythematosus? (2006) (56)
- Altered B cell balance, but unaffected B cell capacity to limit monocyte activation in anti-neutrophil cytoplasmic antibody-associated vasculitis in remission. (2014) (56)
- Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial. (2016) (55)
- Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study. (2004) (55)
- Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy (2012) (54)
- Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis (2011) (54)
- Staphylococcal acid phosphatase binds to endothelial cells via charge interaction; a pathogenic role in Wegener’s granulomatosis? (2000) (54)
- Podocyte expression of MHC class I and II and intercellular adhesion molecule‐1 (ICAM‐1) in experimental pauci‐immune crescentic glomerulonephritis (1994) (53)
- Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. (2009) (53)
- Renal expression of matrix metalloproteinases in human ANCA-associated glomerulonephritis. (2004) (53)
- Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. (2003) (53)
- Pathogenesis and treatment of ANCA-associated vasculitides. (2015) (52)
- Hypoxia-inducible factor-1 as regulator of angiogenesis in rheumatoid arthritis - therapeutic implications. (2010) (52)
- Immune regulatory mechanisms in ANCA-associated vasculitides. (2011) (52)
- The future of damage assessment in vasculitis. (2007) (51)
- Systems analysis of primary Sjögren's syndrome pathogenesis in salivary glands identifies shared pathways in human and a mouse model (2012) (51)
- Overlapping syndromes, undifferentiated connective tissue disease, and other fibrosing conditions (1992) (50)
- FoxP3+ CD4+ T cells in systemic autoimmune diseases: the delicate balance between true regulatory T cells and effector Th-17 cells. (2011) (49)
- Review : Serological markers of disease activity in systemic lupus erythematosus (1995) (49)
- Late breaking clinical trials 1 (2011) (48)
- Expression and regulation of HIF-1alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor (2010) (48)
- Daily physical activity in ankylosing spondylitis: validity and reliability of the IPAQ and SQUASH and the relation with clinical assessments (2013) (47)
- The effect of three years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study (2012) (47)
- Constitutive membrane expression of proteinase 3 (PR3) and neutrophil activation by anti‐PR3 antibodies (2004) (47)
- The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus. (1998) (47)
- Review article: The role of CD4+ T cells in ANCA‐associated systemic vasculitis (2009) (47)
- Are cytokines and chemokines suitable biomarkers for Takayasu arteritis? (2017) (47)
- New insights into the pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis. (2002) (46)
- Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. (2005) (46)
- Granuloma formation in ANCA‐associated vasculitides (2009) (46)
- Opsonization of late apoptotic cells by systemic lupus erythematosus autoantibodies inhibits their uptake via an Fcgamma receptor-dependent mechanism. (2007) (46)
- AGE and their receptor RAGE in systemic autoimmune diseases: An inflammation propagating factor contributing to accelerated atherosclerosis (2009) (46)
- Serum MMP-3 Level as a Biomarker for Monitoring and Predicting Response to Etanercept Treatment in Ankylosing Spondylitis (2011) (46)
- The diagnosis and classification of microscopic polyangiitis. (2014) (46)
- Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2018) (45)
- HLA-DR4, DR13(6) and the ancestral haplotype A1B8DR3 are associated with ANCA-associated vasculitis and Wegener's granulomatosis. (2009) (44)
- Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis? (2018) (44)
- Baseline predictors of response to TNF-&agr; blocking therapy in ankylosing spondylitis (2012) (44)
- Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. (1993) (43)
- Association of common cold with exacerbations in pediatric but not adult patients with tic disorder: a prospective longitudinal study. (2005) (43)
- Membrane-bound proteinase 3 and its receptors: relevance for the pathogenesis of Wegener's Granulomatosis. (2009) (42)
- Increased frequency of circulating IL-21 producing Th-cells in patients with granulomatosis with polyangiitis (GPA) (2013) (42)
- Image analysis: a novel approach for the quantification of antineutrophil cytoplasmic antibody levels in patients with Wegener's granulomatosis. (2003) (42)
- CD4‐Positive Effector Memory T Cells Participate in Disease Expression in ANCA‐Associated Vasculitis (2007) (42)
- Plasma levels of soluble IL-2R, soluble CD30, IL-10 and BAFF during follow-up in PR3-ANCA-associated vasculitis: associations with disease activity and relapse (2006) (41)
- The Future of Biologic Agents in the Treatment of Sjögren’s Syndrome (2007) (40)
- Antineutrophil Cytoplasmic Autoantibodies with Specificity for Myeloperoxidase (1996) (39)
- Risk factors and early detection of atherosclerosis in rheumatoid arthritis (2010) (39)
- Toll-like receptor 9 activation enhances B cell activating factor and interleukin-21 induced anti-proteinase 3 autoantibody production in vitro. (2016) (38)
- The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. (2018) (38)
- Renal expression of endothelial and inducible nitric oxide synthase, and formation of peroxynitrite‐modified proteins and reactive oxygen species in Wegener's granulomatosis (2001) (38)
- Human anti-neutrophil cytoplasm autoantibodies to proteinase 3 (PR3-ANCA) bind to neutrophils. (2005) (38)
- Urinary CD8+ T-cell counts discriminate between active and inactive lupus nephritis (2013) (38)
- Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis (2001) (37)
- Cutaneous reactions to captopril (1984) (36)
- No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis (2009) (35)
- Plasma Factors in Severe Early-Onset Preeclampsia Do Not Substantially Alter Endothelial Gene Expression In Vitro (2005) (35)
- Oral and ocular manifestations in Sjögren's syndrome. (2002) (35)
- Acute hepatitis B in a healthcare worker: a case report of genuine vaccination failure. (2009) (35)
- What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis? (2011) (35)
- Higher anti‐heparan sulphate reactivity during systemic lupus erythematosus (SLE) disease exacerbations with renal manifestations; a long term prospective analysis (1993) (34)
- Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis. (2007) (34)
- Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point? (2011) (34)
- Differential Expression of Granulopoiesis Related Genes in Neutrophil Subsets Distinguished by Membrane Expression of CD177 (2011) (34)
- Is serum HMGB1 a biomarker in ANCA-associated vasculitis? (2013) (34)
- Ig Gene Analysis Reveals Altered Selective Pressures on Ig-Producing Cells in Parotid Glands of Primary Sjögren’s Syndrome Patients (2015) (33)
- Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2017) (33)
- Plasma kynurenine and related measures in tic disorder patients (2007) (33)
- The BVAS is an independent predictor of cardiovascular events and cardiovascular disease-related mortality in patients with ANCA-associated vasculitis: A study of 504 cases in a single Chinese center. (2018) (32)
- Therapy-resistent lupus skin disease successfully treated with rituximab. (2006) (32)
- EASI—The European Autoimmunity Standardisation Initiative (2007) (32)
- Comparison of lacrimal and salivary gland involvement in Sjögren's syndrome. (2003) (32)
- Dysregulated neutrophil--endothelial interaction in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides: implications for pathogenesis and disease intervention. (2011) (31)
- Activation, Apoptosis, and Clearance of Neutrophils in Wegener's Granulomatosis (2005) (30)
- Bronchoalveolar lavage cell analysis and lung function impairment in patients with systemic lupus erythematosus (SLE) (1993) (30)
- Accelerated Atherosclerosis in Patients with Systemic Autoimmune Diseases (2005) (30)
- Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients? (2015) (30)
- Anti-neutrophil cytoplasmic autoantibody pathogenicity revisited: pathogenic versus non-pathogenic anti-neutrophil cytoplasmic autoantibody. (2014) (30)
- Current and future challenges in primary Sjögren's syndrome. (2012) (29)
- Reactivity against Complementary Proteinase-3 Is Not Increased in Patients with PR3-ANCA-Associated Vasculitis (2011) (29)
- Apoptosis in Human Skin: Role in Pathogenesis of Various Diseases and Relevance for Therapy (2005) (28)
- Pauci-immune necrotizing glomerulonephritis. (2010) (28)
- Enhanced endothelium-dependent microvascular responses in patients with Wegener's granulomatosis. (2007) (28)
- Quantification of Epstein-Barr virus-DNA load in lung transplant recipients: a comparison of plasma versus whole blood. (2008) (27)
- Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2015) (27)
- Use of mycophenolic acid in non-transplant renal diseases. (2007) (27)
- Emerging role of high mobility group box 1 in ANCA-associated vasculitis. (2015) (27)
- Genetic loci of Staphylococcus aureus associated with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (2017) (26)
- Cytokines and soluble adhesion molecules in children and adolescents with a tic disorder (2010) (26)
- Native and recombinant proteins to analyze auto-antibodies to myeloperoxidase in pauci-immune crescentic glomerulonephritis. (2001) (26)
- Advances in pathogenesis and treatment of ANCA-associated vasculitis. (2014) (25)
- Fcγ receptors in the initiation and progression of systemic lupus erythematosus (2003) (25)
- Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine. (2010) (25)
- Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab (2014) (25)
- The R-H polymorphism of FCgamma receptor IIa as a risk factor for systemic lupus erythematosus is independent of single-nucleotide polymorphisms in the interleukin-10 gene promoter. (2002) (25)
- Absence of In Vivo Generalized Pro-Inflammatory Endothelial Activation in Severe, Early-Onset Preeclampsia (2005) (24)
- Increased seroreactivity in tic disorder patients to a 60 kDa protein band from a neuronal cell line (2003) (24)
- Membrane proteinase 3 expression on resting neutrophils as a pathogenic factor in PR3-ANCA-associated vasculitis. (2003) (24)
- Complement is crucial in the pathogenesis of ANCA-associated vasculitis. (2013) (24)
- Genetics of ANCA-associated vasculitides. (2002) (24)
- Usefulness of antineutrophil cytoplasmic autoantibodies in diagnosing and managing systemic vasculitis. (2016) (23)
- Pulmonary: renal syndrome with a focus on anti-GBM disease. (2011) (23)
- Pulmonary diffusing capacity disturbances are related to nailfold capillary changes in patients with Raynauds's phenomenon with and without an underlying connective tissue disease (1990) (23)
- Towards precision medicine in ANCA-associated vasculitis. (2018) (23)
- How to assess treatment efficacy in Sjögren's syndrome? (2012) (23)
- Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies. (2000) (23)
- Low anti-staphylococcal IgG responses in granulomatosis with polyangiitis patients despite long-term Staphylococcus aureus exposure (2015) (23)
- Cell-mediated immune responses to inactivated trivalent influenza-vaccination are decreased in patients with common variable immunodeficiency. (2011) (22)
- Patients with Wegener's granulomatosis: a long-term follow-up study. (2010) (22)
- The Last Classification of Vasculitis (2008) (22)
- The association of serum calprotectin (S100A8/S100A9) levels with disease relapses in PR3‐ANCA‐associated vasculitis (2016) (22)
- M2 macrophage is the predominant phenotype in airways inflammatory lesions in patients with granulomatosis with polyangiitis (2017) (22)
- The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2016) (21)
- Successful treatment of ulcerating livedo reticularis with infusions of prostacyelin (1992) (21)
- Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis (2012) (21)
- Anti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis: where to go? (2011) (21)
- Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial (2011) (21)
- Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2019) (21)
- Cell-mediated immune responses to influenza vaccination in Wegener's granulomatosis (2009) (21)
- Diversity of PR3-ANCA Epitope Specificity in Wegener's Granulomatosis. Analysis Using the Biosensor Technology (2003) (21)
- High mobility group box 1 ( HMGB 1 ) and anti-HMGB 1 antibodies and their relation to disease characteristics in systemic lupus erythematosus (2011) (20)
- Quantitation of antibodies to nucleoribonucleoprotein by ELISA: relation between antibody levels and disease activity in patients with connective tissue disease. (1985) (20)
- Inflammatory clearance of apoptotic cells after UVB challenge (2007) (20)
- Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis? (2012) (19)
- Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. (2016) (19)
- B-cell populations and sub-populations in Sjögren's syndrome. (2012) (19)
- Fluctuations in anti-nRNP levels in patients with mixed connective tissue disease are related to disease activity as part of a polyclonal B cell response. (1986) (19)
- Absence of Cross-Reactivity to Myeloperoxidase of Anti-Thyroid Microsomal Antibodies in Patients with Autoimmune Thyroid Diseases (2001) (19)
- Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis (2014) (19)
- Anti-neutrophil cytoplasm autoantibodies (ANCA) in autoimmune liver diseases. (1999) (18)
- Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis (2012) (17)
- Complement system activation in ANCA vasculitis: A translational success story? (2015) (17)
- Standardised assessment of membrane proteinase 3 expression. Analysis in ANCA-associated vasculitis and controls (2007) (17)
- Role for CaMKII Inhibition in Rheumatoid Arthritis (2009) (17)
- The net effect of ANCA on neutrophil extracellular trap formation. (2018) (17)
- The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. (2019) (17)
- Autoantibodies vex the vasculature (2008) (17)
- Autoantibodies to myeloperoxidase: clinical and pathophysiological significance (1998) (17)
- High mobility group box 1 serum levels are increased in Behçet's disease, but not associated with disease activity or disease manifestations. (2015) (17)
- Interstitial lung disease and myositis in a patient with simultaneously occurring sarcoidosis and scleroderma. (1993) (16)
- Extended Follow-up of Treatment with Rituximab Versus Cyclophosphamide for Remission-Induction of ANCA-Associated Vasculitis : Which Subsets Are At Greatest Risk for Flare? (2011) (16)
- Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis (2018) (16)
- Antinuclear and antinative DNA antibodies during captopril treatment. (2009) (16)
- T FcRIIIA158F allele is a risk factor for systemic lupus erythematosus (1998) (16)
- Lack of Association of C-C Chemokine Receptor 5 Δ32 Deletion Status with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Lupus Nephritis, and Disease Severity (2010) (16)
- Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2019) (16)
- Rituximab treatment in primary Sjogren's syndrome : A double-blind placebo controlled trial (2008) (15)
- What is new with anti-neutrophil cytoplasmic antibodies: diagnostic, pathogenetic and therapeutic implications. (1999) (15)
- Elevated binding of D8/17-specific monoclonal antibody to B lymphocytes in Tic disorder patients. (2004) (15)
- Small artery elasticity is decreased in patients with systemic lupus erythematosus without increased intima media thickness (2010) (14)
- Selective elimination of pathogenic synovial fluid T-cells from rheumatoid arthritis and juvenile idiopathic arthritis by targeted activation of Fas-apoptotic signaling. (2011) (14)
- Anti-myeloperoxidase antibodies in Churg-Strauss syndrome (1993) (13)
- What is the evidence for prophylactic antibiotic treatment in patients with systemic vasculitides? (2011) (13)
- HLA-DR 4 , DR 13 ( 6 ) and the ancestral haplotype A 1 B 8 DR 3 are associated with ANCA-associated vasculitis and Wegener ’ s granulomatosis (2009) (12)
- The impact factor of rheumatology journals: an analysis of 2008 and the recent 10 years (2010) (12)
- Autoantibodies during captopril treatment. (1985) (12)
- Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis (2017) (12)
- Pulmonary diffusing capacity disturbances are related to nailfold capillary changes in patients with Raynaud's phenomenon with and without an underlying connective tissue disease. (1990) (12)
- Fcgamma receptors in the initiation and progression of systemic lupus erythematosus. (2003) (11)
- Increased accumulation of advanced glycation endproducts in patients with Wegener's granulomatosis (2009) (11)
- Autoantibody Standardization in the Netherlands (2009) (11)
- Treatment approaches in primary Sjogren syndrome. (2010) (11)
- Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2017) (11)
- High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins (2015) (11)
- Retinoid X receptor beta polymorphisms do not explain functional differences in vitamins D and A response in Antineutrophil cytoplasmic antibody associated vasculitis patients (2009) (10)
- Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA‐Associated Vasculitis (2016) (9)
- Antineutrophil cytoplasmic antibodies (ANCA) and vasculitis (1990) (9)
- Esophageal hypomotility in primary and secondary Raynaud's phenomenon: comparison of esophageal scintigraphy with manometry. (1995) (9)
- Pro: Cyclophosphamide in lupus nephritis. (2016) (9)
- Recombinant protein to analyze autoantibodies to proteinase 3 in systemic vasculitis. (2003) (9)
- 9 Laboratory findings in the vasculitides (1997) (9)
- Prognostic Value of Renal Hemodynamic Characteristics in Patients with Proliferative Lupus Nephritis (2007) (8)
- Decreased capillary permeability and capillary density in patients with systemic sclerosis using large-window sodium fluorescein videodensitometry of the ankle. (2008) (8)
- Expression of Class II-MHC Antigens on Alveolar and Bronchiolar Epithelial Cells in Fibrosing Alveolitis (1986) (7)
- Treatment of ANCA-Associated Vasculitis, Where to Go? (2012) (7)
- Immunoglobulin Concentrations and Infection Risk Among Patients with ANCA-Associated Vasculitis Treated with Rituximab or Cyclophosphamide. (2011) (7)
- Autoantibodies against glomerular endothelial cells in anti‐neutrophil cytoplasmic autoantibody‐associated systemic vasculitis (2009) (7)
- L3. Are mononuclear cells predominant actors of endothelial damage in vasculitis? (2013) (7)
- FSAP‐mediated nucleosome release from late apoptotic cells is inhibited by autoantibodies present in SLE (2016) (7)
- 13 – ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES WITH SPECIFICITY FOR MYELOPEROXIDASE (2007) (7)
- Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis (2021) (7)
- Skin Autofluorescence, as Marker of Accumulation of Advanced Glycation Endproducts and of Cumulative Metabolic Stress, Is Not Increased in Patients with Systemic Sclerosis (2011) (7)
- Pulmonary function in patients presenting with Raynaud's phenomenon without an underlying connective tissue disease. A prospective, longitudinal study. (1989) (6)
- Hypoxia inducible factor-1-alpha (HIF-1α) is related to both angiogenesis and inflammation in rheumatoid arthritis (2006) (6)
- Dying neutrophils in ANCA-associated vasculitis: good or bad guys? (2002) (6)
- Vasculitis syndromes: Peripheral neuropathy in AAV—when vasculitis hits a nerve (2012) (6)
- Combined brain and heart magnetic resonance imaging in systemic vasculitides: fiction or real need? (2018) (5)
- Antineutrophil cytoplasmic antibodies (ANCA): current perspectives (1996) (5)
- Combined Brain/Heart Magnetic Resonance Imaging in Systemic Lupus Erythematosus (2020) (5)
- Anti-Neutrophil Cytoplasmic Antibodies (ANCA): New Tools in the Diagnosis and Follow-Up of Necrotizing Glomerulonephritis and Vasculitis (1991) (5)
- B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis. (2015) (5)
- Efficacy Of Glucocorticoids To Treat Limited Flares In ANCA-Associated Vasculitis (2013) (5)
- Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2018) (5)
- Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis? (2014) (5)
- Renal vasculitis in 2012: Reclassification and the introduction of biologicals (2013) (5)
- Antimyeloperoxidase-associated Proliferative Glomerulonephritis: An Animal Model By Elisabeth Brouwer,* Minke G. Huitema,* Pieter A. Klok,~ (1993) (5)
- Prevention of relapsing disease in anti-neutrophil cytoplasmic antibody related necrotizing small-vessel vasculitis: the role for autoantibody guided and anti-bacterial treatment (2001) (5)
- Disease Activity, ANCA-Type, and Lipid Levels in ANCA-Associated Vasculitis. (2019) (5)
- Response to ‘T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?’ (2014) (4)
- Co-expression of CD177 and membrane proteinase 3 on neutrophils in ANCA-associated vasculitis: Anti-PR3 mediated neutrophil activation is independent of CD177 expression (2008) (4)
- The role of bacterial infections for the initiation and exacerbation of systemic vasculitis. (2004) (4)
- Novel territory for neutrophils in the pathogenesis of ANCA-associated vasculitides. (2009) (4)
- Association of poly(ADP-ribose) polymerase 1 and a novel candidate locus, LOC127086, with systemic lupus erythematosus (2007) (4)
- Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis (2020) (4)
- Hypoxia inducible factor-1-alpha ( HIF-1 alpha ) is related to both angiogenesis and inflammation in rheumatoid arthritis (2018) (4)
- Increased frequency of circulating follicular helper T cells (T-fh) in patients with WG (2011) (3)
- Pulmonary arterial hypertension in systemic lupus erythematosus: should we bother? (2009) (3)
- Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA‐Associated Vasculitis (2021) (3)
- Do apoptotic cells accumulate in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation? Comment on the article by Kuhn et al. (2006) (3)
- Smoking and increased apoptosis in patients with systemic lupus erythematosus: comment on the article by Costenbader et al. (2004) (3)
- Refractory disease in autoimmune diseases. (2011) (3)
- Standard therapeutic regimens for vasculitis (2001) (3)
- Pulmonary Manifestations of Systemic Vasculitides (1998) (3)
- CpG triggers ANCA production by blood-derived B cells from ANCA-associated vasculitis patients in clinical remission (2009) (3)
- Evolving concepts in pathogenesis and treatment of ANCA‐associated systemic vasculitides (2009) (3)
- Preferential Binding of Anti-Neutrophil Cytoplasmic Antibodies to an Unexpected Epitope of a Chimeric Proteinase 3 Mutant (2019) (2)
- Damage in ANCA-associated vasculitis: Preliminary evidence for the ANCA-associated vasculitis index of damage (AVID). (2006) (2)
- The Relation Between Daily Physical Activity Measured with the Accelerometer and Clinical Assessments in Patients with Ankylosing Spondylitis (2011) (2)
- Are Anti-Nrnp Levels Specific Guides for Assessing Disease Activity in Patients with (Mixed) Connective Tissue Disease? (1985) (2)
- B-cell-targeted therapy in rheumatic diseases (2006) (2)
- Retreatment With Rituximab In The Rituximab In ANCA-Associated Vasculitis (RAVE) Trial (2013) (2)
- Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2022) (2)
- Autoantibodies and Vascular Inflammation (2012) (2)
- Leukocyte Cell Adhesion Molecules in Vasculitis (2001) (2)
- University of Groningen Reactivity against Complementary Proteinase-3 Is Not Increased in Patients with PR3-ANCA- Associated Vasculitis Tadema, (2011) (2)
- SP0001 What Is New in Vasculitis? (2016) (2)
- Laboratory diagnosis of ANA, anti-dsDNA- and anti-ENA- antibodies; recommendations following the outcomes of a questionaire (2010) (2)
- Clinical immunology--autoimmunity in the Netherlands. (2014) (2)
- Rituximab treatment in Sjogren's syndrome: Clinical-histological evidence of the efficacy of B-cell depletion (2006) (2)
- Antibodies Against C1q (2019) (2)
- What is new in systemic vasculitis? (2000) (2)
- AB0910 Validity and reliability of the IPAQ and squash to assess daily physical activity in patients with ankylosing spondylitis (2013) (2)
- Activation of a Latent Epitope Causing Differential Binding of Anti-Neutrophil Cytoplasmic Antibodies to Proteinase 3 (2022) (1)
- Health-related quality of life, employment and disability in patients with Sjo¨gren’s syndrome (2009) (1)
- Predictive Value of Selected Markers of Inflammation and Platelet Activation for Complete Remission in ANCA-Associated Vasculitis (2012) (1)
- Letter to the Editor (Matters Arising) (2006) (1)
- Why rheumatologists should be involved in the treatment of lupus nephritis (2008) (1)
- 222. PREFERENTIAL BINDING TO AN UNEXPECTED EPITOPE OF A CHIMERIC RECOMBINANT PROTEINASE 3 VARIANT BY ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES (2019) (1)
- Etiopathogenesis of systemic autoimmune diseases. (2013) (1)
- Occurrence of antibodies to bactericidal permeability increasing protein (BPI) in sera with perinuclear antineutrophil cytoplasmic antibody (P-ANCA) activity (1997) (1)
- Disease-modifying Therapy in Vasculitides (2012) (1)
- Antibody and cell-mediated responses to influenza vaccination in patients with systemic lupus erythematosus and, healthy controls (2008) (1)
- Primary Sjogren's syndrome: Retreatment with rituximab and long-term follow-up. (2006) (1)
- Increased Frequency of Circulating Follicular Helper T-Cells (T-FH) in Patients with Granulomatosis with Polyangiitis. (2011) (1)
- HMGB1 Is An Important Mediator in Cutaneous Inflammation in Systemic Lupus Erythematosus (SLE) (2011) (1)
- Anti‐neutrophil cytoplasmic antibodies and the endothelium: many ways to vasculitis (1997) (1)
- 172. THE ASSOCIATION OF DIFFERENCES IN LIPID PARAMETERS WITH DISEASE ACTIVITY IN ANCA-ASSOCIATED VASCULITIS (AAV) (2019) (1)
- Chapter 12 – Antineutrophil Cytoplasmic Autoantibodies with Specificity for Myeloperoxidase (2014) (1)
- ANCA-associated vasculitis: pathogenesis revisited (2004) (1)
- Autoantibodies as Biomarkers for ANCA-Associated Vasculitides (2011) (1)
- Systems Biology Analysis of Sjögren’s Syndrome and MALT Lymphoma Development in Parotid Glands (2008) (1)
- In reply to 'rituximab and B-cell return in ANCA-associated vasculitis'. (2014) (1)
- Chapter VI Anti-CD 3-induced and anti-Fas-induced apoptosis in systemic lupus erythematosus ( SLE ) (2001) (1)
- ANCA: their clinical relevance (1996) (1)
- VALIDITY AND RELIABILITY OF THE IPAQ AND SQUASH TO ASSESS DAILY PHYSICAL ACTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS (2012) (1)
- Circulating leukocytes in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis have increased expression of activation markers, but no increased expression of adhesion molecules (1997) (1)
- University of Groningen Differential expression of granulopoiesis related genes in neutrophil subsets distinguished by membrane expression of CD177 Hu, (2014) (1)
- Opsonization of late apoptotic cells by systemic lupus erythematosus (SLE) autoantibodies inhibits their uptake via an Fc gamma R-dependent mechanism (2007) (1)
- PREVALENCE OF VERTEBRAL FRACTURES IN ANKYLOSING SPONDYLITIS PATIENTS WITH ACTIVE DISEASE (2010) (0)
- CHAPTER 2 CD 4-positive effector memory T-cells participate in disease expression in ANCA-associated vasculitis (2019) (0)
- CHAPTER 6 REDUCED NUMBER AND IMPAIRED FUNCTION OF CIRCULATING PROGENITOR CELLS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (2019) (0)
- Small artery elasticity is decreased in patients with systemic lupus erythematosus without atherosclerosis and is related to accumulation of advanced glycation end products (2008) (0)
- ANCA pathogenicity revisited: pathogenic versus non-pathogenic ANCA (2016) (0)
- Chapter 4 Image analysis ; a novel approach for the quantification of antineutrophil cytoplasmic antibody levels in patients with Wegener ’ s Granulomatosis (2018) (0)
- Systemic auto immune diseases: from pathogenesis to treatment. (2003) (0)
- Induction of HIF-1alpha expression in monocytic cells during differentiation under nowhypoxic conditions and effect on production of pro-angiogenic factors (2007) (0)
- Identification of autoantibody biomarkers for primary Sjögren's syndrome using protein microarrays (2011) (0)
- [Vasculitis: a spectrum of divergent disease aspects with a common immunopathogenesis?]. (1987) (0)
- Re-Occurring Proteinuria in a SLE Patient: Always Lupus Nephritis? (2017) (0)
- University of Groningen Sjogren ' s syndrome (2010) (0)
- Pathogenic mechanisms of autoantibodies (2007) (0)
- Reduced number and impaired function of endothelial progenitor cells in patients with systemic lupus erythematosus (2007) (0)
- Increased expression of costimulatory markers CD134 and CD80 on IL-17 producing T-cells in patients with systemic lupus erythematosus (2017) (0)
- CHAPTER 7 ACCELERATED ATHEROSCLEROSIS IN PATIENTS WITH WEGENER ’ S GRANULOMATOSIS (2019) (0)
- Skin autofluorescence, as measure of cumulative metabolic and oxidative stress, in relation to lipids in patients with systemic sclerosis (2008) (0)
- University of Groningen Hypoxia inducible factor-1-alpha ( HIF-1 alpha ) is related to both angiogenesis and inflammation in rheumatoid arthritis (2017) (0)
- Chapter 5 Native and recombinant proteins to analyze autoantibodies to myeloperoxidase in pauci-immune crescentic glomerulonephritis (2017) (0)
- Genetic loci of Staphylococcus aureus associated with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (2017) (0)
- List of Contributors (2019) (0)
- Pathogenetic and clinical aspects of ANCA-associated vasculitis (2017) (0)
- Vasculitis: current issues IP93. Pathogenesis of Vasculitis (2011) (0)
- New etiopathogenic knowledge, or politics? Comment on the article by Falk et al Reply (2011) (0)
- CHANGES IN BONE TURNOVER MARKERS IN PATIENTS WITH ANKYLOSING SPONDYLITIS DURING THE FIRST 6 MONTHS OF TNF-ALPHA BLOCKING THERAPY (2010) (0)
- B cell phenotype and function in granulomatosis with polyangiitis Land (2016) (0)
- Full Review B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis (2015) (0)
- Separate association with susceptibility or protection to systemic lupus erythematosus of interferon regulatory factor 5 (IRF5) polymorphisms (2007) (0)
- The Specificity of the Autoimmune Response in Vasculitis (1991) (0)
- University of Groningen Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors Hettema, (2015) (0)
- Lupus. Preface. (2008) (0)
- University of Groningen Low anti-staphylococcal IgG responses in granulomatosis with polyangiitis patients despite long-term Staphylococcus aureus exposure Glasner, (2015) (0)
- CHAPTER 1 ACCELERATED ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES (2008) (0)
- Quantitation ofantibodies tonucleoribonucleoprotein byELISA: relation between antibody levels anddisease activity inpatients withconnective tissue disease (1985) (0)
- antibodies antigens referred to as anti-nuclear assessment of autoantibodies to cellular International recommendations for the (2013) (0)
- [The significance of determining humoral defense factors: Ig isotypes, specific antibodies and complement]. (1988) (0)
- Diagnostic and pathogenetic significance of autoantibodies in autoimmune liver diseases (2001) (0)
- CHAPTER 8 PROGRESSION OF ATHEROSCLEROSIS IN PATIENTS WITH WEGENER ’ S GRANULOMATOSIS : A LONG-TERM FOLLOW-UP STUDY (2019) (0)
- OP0058 Using Mass Spectrometry To Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in Anca-Associated Vasculitis (2016) (0)
- The Hochberg: Rheumatology, 7e : Biology and immunopathogenesis of vasculitis Elisabeth Brouwer • Peter Heeringa • Cees G.M. Kallenberg (2018) (0)
- CHAPTER 6 Functional defect of circulating regulatory CD 4 + T-cells in patients with Wegener ’ s granulomatosis in remission (2018) (0)
- Influenza vaccination in ANCA-associated vasculitis Reply (2009) (0)
- Chapter 7 ANCA-Associated Systemic Vasculitides: Mechanisms (2007) (0)
- Serum levels of soluble receptor for advanced glycation end products in AA amyloidosis are increased and related to loss of renal function (2010) (0)
- Plenary and parallel sessions (2001) (0)
- Prevention of relapses in antineutrophil cytoplasmic antibody associated vasculitis by treatment based on autoantibody levels as detected by solid phase assay: a preliminary report (2001) (0)
- [Agranulocytosis caused by niflumic acid (Infaryl)]. (1979) (0)
- Induction of HIF-1 alpha expression during monocyte-macrophage differentiation and effect on production of pro-angiogenic factors (2007) (0)
- C5a primes neutrophils for ANCA-mediated activation: role of P38 mitogen-activated protein kinase (2009) (0)
- Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism (2023) (0)
- THU0265 Early change in bone resorption predicts discontinuation of tumor necrosis factor-alpha blocking therapy in patients with ankylosing spondylitis (2013) (0)
- Chapter 11 Neurobiology of Tourette ’ s syndrome : do immune factors really matter ? (2018) (0)
- SP0149 Endothelial Damage in Anca-Associated Vasculitis (AAV) (2015) (0)
- Identifying relevant determinants of in-hospital time to diagnosis for ANCA-associated vasculitis patients (2022) (0)
- High mobility group box 1 levels are not associated with subclinical carotid atherosclerosis in patients with granulomatosis with polyangiitis but are reduced by glucocorticoids and statins (2012) (0)
- Increased Circulating FoxP3(+) T-Cells in Patients with Granulomatosis with Polyangiitis Are Attributed to an Increase in the Non-Suppressor FoxP3(Low) CD45RO(+) T-Reg Cell Subpopulation. (2012) (0)
- Apoptosis and autoantibodies in systemic lupus erythematosus (2001) (0)
- Fluctuations inanti-nRNP levels inpatients with mixedconnective tissue disease arerelated todisease activity aspartofapolyclonal Bcell response (1986) (0)
- FRI0295 Syndesmophytes are associated with higher bone turnover in ankylosing spondylitis patients with active disease (2013) (0)
- CHAPTER 9 ENHANCED ENDOTHELIUM-DEPENDENT MICROVASCULAR RESPONSES IN PATIENTS WITH WEGENER ’ S GRANULOMATOSIS (2019) (0)
- ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES (2008) (0)
- Improvement in Ankylosing Spondylitis Disease Activity Score in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor-Alpha Blocking Therapy (2011) (0)
- Unraveling the identity of FoxP3+ regulatory T-cells in GPA-patients (2013) (0)
- Quality of life, employment and disability in patients with Sjogren's syndrome (2008) (0)
- Commentary Staphylococcus aureus and Wegener ’ s granulomatosis (2015) (0)
- Transplantation, immunology, inflammation (2002) (0)
- Lupus Erythematosus ( SLE ) : relation to lymphocyte activation and disease activity (2001) (0)
- CHAPTER 3 Disturbed Th 1 , Th 2 , Th 17 and Treg balance in patients with systemic lupus erythematosus (2017) (0)
- 154 – Biology and immunopathogenesis of vasculitis (2015) (0)
- P2_19 High Bartonella Seroprevalence in Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2017) (0)
- 053. CLINICAL UTILITY OF SERIAL MEASUREMENTS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES TARGETING PROTEINASE 3 IN ANCA-ASSOCIATED VASCULITIS (2019) (0)
- TUMOR NECROSIS FACTOR-ALPHA BLOCKING THERAPY IMPROVES QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN DAILY CLINICAL PRACTICE (2010) (0)
- Opponent's comments. (2016) (0)
- [The role of perinuclear antineutrophil granulocytes cytoplasmic antibodies in the diagnosis of vasculitis and chronic inflammatory diseases]. (1996) (0)
- Relationship between age and bone turnover markers in patients with active ankylosing spondylitis (2009) (0)
- Endothelial Progenitor Cells and cardiovascular risk in patients with Early Rheumatoid Arthritis (2014) (0)
- Acute hepatitis B in a healthcare worker: A lesson in awareness of failure of hepatitis B vaccination (2009) (0)
- SAT0370 Antineutrophil Cytoplasmic Antibody (ANCA) Type and Body Mass Index in Anca-Associated Vasculitis (2016) (0)
- Value of positron emission tomography in diagnosis and follow-up of patients with Takayasu arteritis (2003) (0)
- Co-trimoxazole in Wegener's granulomatosis - Reply (1996) (0)
- C URRENT OPINION Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis? (2014) (0)
- Auto-antigen expression of proteinase 3 on the membrane of neutrophils is dependent on phosphatidylinositol 3-kinase and P38 MAPkinase activity (2006) (0)
- SAT0369 Weight Gain in Anca-Associated Vasculitis Is Independent of Glucocorticoid Dosing (2016) (0)
- CYP450 polymorphism as a predictor of adverse effects and therapy response in patients with ANCA-AAV (2011) (0)
- University of Groningen Is serum HMGB 1 a biomarker in ANCA-associated vasculitis ? (2013) (0)
- APRIL and BAFF Levels After Rituximab Treatment in Patients with Primary Sjogren's Syndrome: A Placebo-Controlled Clinical Trial (2011) (0)
- Progression and treatment evaluation in diseases affecting salivary glands (2010) (0)
- [A patient with recurrent polychondritis, vasculitis and local focal glomerulonephritis]. (1988) (0)
- Glands of Primary Sjögren's Syndrome Pressures on Ig-Producing Cells in Parotid Ig Gene Analysis Reveals Altered Selective (2015) (0)
- Interleukin 10–1082 promoter polymorphism in inflammatory bowel disease is not associated with disease susceptibility or severity (1999) (0)
- Chapter 7 Plasma kynurenine and tryptophan in Tourette ’ s and chronic motor tic disorder (2018) (0)
- Leucocyte TLR expression in ANCA-AAV : differential expression by monocytes and NK cells (2011) (0)
- Experimental Therapies in Sjögren’s Syndrome (2011) (0)
- Systemic vasculitides, an introduction (2001) (0)
- Early Reconstitution of Autoreactive B-Cells After Rituximab Treatment in Primary Sjogren's Syndrome (2011) (0)
- B-Cell Depletion By Rituximab Affects the Distribution of Effector Th-Cell Subsets in Patients with ANCA Associated Vasculitis (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Cees G. M. Kallenberg?
Cees G. M. Kallenberg is affiliated with the following schools: